This trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed).

For some patients, blinatumomab is not effective. There is evidence that this is caused by a lack of activity from the patient’s immune system, which is needed for blinatumomab to work. Nivolumab is a medicine that is used to boost a patient’s immune system and this study is evaluating if nivolumab might make blinatumomab work better.

This trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms (MPNs).

This research study is for people who have been diagnosed with a form of Acute Lymphoblastic Leukemia (ALL) called Philadelphia chromosome positive (Ph+) ALL or ABL-class Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL).

Leukemia is a type of cancer that occurs in the blood. It develops in the bone marrow, which is the soft, spongy center of the bones that produces the three major blood cells: white blood cells to fight infection; red blood cells that carry oxygen to the body; and platelets that help blood clot and stop bleeding.

The purpose of this study is to test if an investigational study drug, pegozafermin, is safe and effective in treating patients with MASH metabolic dysfunction-associated steatohepatitis (MASH).

The purpose of this study is to determine if investigational Ropeginterferon alfa-2b-njft (P1101) is safe and effective at treating participants with pre-fibrotic/early primary myelofibrosis.

Investigational means that Ropeginterferon alfa-2b-njft (P1101) is not approved by the U.S. Food and Drug Administration.

The purpose of this study is to learn about people’s experiences with Crystal Meth Anonymous (CMA), a 12-step community-based support group for people who use crystal methamphetamine. 

This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal women with a history of hormone receptor-positive breast cancer and obesity.

The investigators aim to understand whether participants are willing and able to take this medication once weekly via subcutaneous injection for 6 months and whether it may help improve weight and overall health.

The purpose of this study is to compare the usual treatment with hormonal therapy medications to treatment with low-dose tamoxifen for patients with molecular low-risk early-stage breast cancer.   

This study has 2 study groups. Participants will be randomized by a computer to assign them to one of the study groups.

This study is being done to evaluate if a type of SRS radiation treatment called fractionated SRS (or FSRS) completed over 3 treatments to the areas of cancer in the brain delay the time until the cancer worsens or returns compared to the usual SRS given in 1 treatment.

Participants will be randomized into one of two treatment groups. Randomization is like flipping a coin and there is a 50/50 chance of being assigned to either group.

The purpose of this study is to provide patients with AMTAGVI (lifileucel) that is Out of Specification for Commercial Release.
   
In this study, AMTAGVI will be given intravenously (meaning through a needle in the vein directly into the blood).

Participation is expected to last up to 24 months.